Indaptus Therapeutics (NASDAQ:INDP) Posts Earnings Results

Posted by Brian Himes on Aug 13th, 2026

Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.57) by $1.55, Zacks reports.

Indaptus Therapeutics Price Performance

NASDAQ:INDP traded up $0.04 during trading hours on Thursday, hitting $1.06. 92,854 shares of the company traded hands, compared to its average volume of 111,264. Indaptus Therapeutics has a twelve month low of $0.92 and a twelve month high of $8.57. The firm has a 50-day moving average of $2.64 and a 200 day moving average of $2.23.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Friday, July 17th. Wall Street Zen raised shares of Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Check Out Our Latest Report on Indaptus Therapeutics

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 7.06% of the company’s stock.

About Indaptus Therapeutics

(Get Free Report)

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.